749 related articles for article (PubMed ID: 32634603)
21. Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain.
Pérez-Belmonte LM; López-Carmona MD; Quevedo-Marín JL; Ricci M; Martín-Carmona J; Sanz-Cánovas J; López-Sampalo A; Martín-Escalante MD; Bernal-López MR; Gómez-Huelgas R
Int J Environ Res Public Health; 2020 Sep; 17(18):. PubMed ID: 32961675
[TBL] [Abstract][Full Text] [Related]
22. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
[TBL] [Abstract][Full Text] [Related]
23. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
Vargas M; Servillo G; Einav S
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8592-8605. PubMed ID: 32894567
[TBL] [Abstract][Full Text] [Related]
24. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
Choy KT; Wong AY; Kaewpreedee P; Sia SF; Chen D; Hui KPY; Chu DKW; Chan MCW; Cheung PP; Huang X; Peiris M; Yen HL
Antiviral Res; 2020 Jun; 178():104786. PubMed ID: 32251767
[TBL] [Abstract][Full Text] [Related]
25. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.
Liu T; Luo S; Libby P; Shi GP
Pharmacol Ther; 2020 Sep; 213():107587. PubMed ID: 32470470
[TBL] [Abstract][Full Text] [Related]
26. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies.
Sharma A; Tiwari S; Deb MK; Marty JL
Int J Antimicrob Agents; 2020 Aug; 56(2):106054. PubMed ID: 32534188
[TBL] [Abstract][Full Text] [Related]
27. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
Cao B; Wang Y; Wen D; Liu W; Wang J; Fan G; Ruan L; Song B; Cai Y; Wei M; Li X; Xia J; Chen N; Xiang J; Yu T; Bai T; Xie X; Zhang L; Li C; Yuan Y; Chen H; Li H; Huang H; Tu S; Gong F; Liu Y; Wei Y; Dong C; Zhou F; Gu X; Xu J; Liu Z; Zhang Y; Li H; Shang L; Wang K; Li K; Zhou X; Dong X; Qu Z; Lu S; Hu X; Ruan S; Luo S; Wu J; Peng L; Cheng F; Pan L; Zou J; Jia C; Wang J; Liu X; Wang S; Wu X; Ge Q; He J; Zhan H; Qiu F; Guo L; Huang C; Jaki T; Hayden FG; Horby PW; Zhang D; Wang C
N Engl J Med; 2020 May; 382(19):1787-1799. PubMed ID: 32187464
[TBL] [Abstract][Full Text] [Related]
28. Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus.
Shaikh K; Shrestha C; Dutta D
J Pak Med Assoc; 2020 May; 70(Suppl 3)(5):S69-S73. PubMed ID: 32515383
[TBL] [Abstract][Full Text] [Related]
29. Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients.
Li L; Wang X; Wang R; Hu Y; Jiang S; Lu X
Drug Des Devel Ther; 2020; 14():3001-3013. PubMed ID: 32801640
[TBL] [Abstract][Full Text] [Related]
30. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review.
Hernandez AV; Roman YM; Pasupuleti V; Barboza JJ; White CM
Ann Intern Med; 2020 Aug; 173(4):287-296. PubMed ID: 32459529
[TBL] [Abstract][Full Text] [Related]
31. Pharmacotherapy in COVID-19; A narrative review for emergency providers.
Mehta N; Mazer-Amirshahi M; Alkindi N; Pourmand A
Am J Emerg Med; 2020 Jul; 38(7):1488-1493. PubMed ID: 32336586
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
Trials; 2020 May; 21(1):422. PubMed ID: 32448345
[TBL] [Abstract][Full Text] [Related]
33. Understanding COVID-19: From Origin to Potential Therapeutics.
Moazzam M; Sajid MI; Shahid H; Butt J; Bashir I; Jamshaid M; Shirazi AN; Tiwari RK
Int J Environ Res Public Health; 2020 Aug; 17(16):. PubMed ID: 32823901
[TBL] [Abstract][Full Text] [Related]
34. Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.
Mallhi TH; Ahmad A; Butt MH; Misbah S; Khan YH; Alotaibi NH
J Coll Physicians Surg Pak; 2020 Oct; 30(10):124-128. PubMed ID: 33115586
[TBL] [Abstract][Full Text] [Related]
35. Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action.
Khan Z; Karataş Y; Rahman H
Adv Ther; 2020 Jun; 37(6):2575-2579. PubMed ID: 32350686
[TBL] [Abstract][Full Text] [Related]
36. COVID-19 in Children: Clinical Approach and Management.
Sankar J; Dhochak N; Kabra SK; Lodha R
Indian J Pediatr; 2020 Jun; 87(6):433-442. PubMed ID: 32338347
[TBL] [Abstract][Full Text] [Related]
37. Teicoplanin: an alternative drug for the treatment of COVID-19?
Baron SA; Devaux C; Colson P; Raoult D; Rolain JM
Int J Antimicrob Agents; 2020 Apr; 55(4):105944. PubMed ID: 32179150
[TBL] [Abstract][Full Text] [Related]
38. Drug treatments for covid-19: living systematic review and network meta-analysis.
Siemieniuk RA; Bartoszko JJ; Zeraatkar D; Kum E; Qasim A; Martinez JPD; Izcovich A; Lamontagne F; Han MA; Agarwal A; Agoritsas T; Azab M; Bravo G; Chu DK; Couban R; Devji T; Escamilla Z; Foroutan F; Gao Y; Ge L; Ghadimi M; Heels-Ansdell D; Honarmand K; Hou L; Ibrahim Q; Khamis A; Lam B; Mansilla C; Loeb M; Miroshnychenko A; Marcucci M; McLeod SL; Motaghi S; Murthy S; Mustafa RA; Pardo-Hernandez H; Rada G; Rizwan Y; Saadat P; Switzer C; Thabane L; Tomlinson G; Vandvik PO; Vernooij RW; Viteri-García A; Wang Y; Yao L; Zhao Y; Guyatt GH; Brignardello-Petersen R
BMJ; 2020 Jul; 370():m2980. PubMed ID: 32732190
[TBL] [Abstract][Full Text] [Related]
39. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
[TBL] [Abstract][Full Text] [Related]
40. [Chloroquine as a possible treatment for COVID-19].
Coumou J; de Vries PJ
Ned Tijdschr Geneeskd; 2020 Mar; 164():. PubMed ID: 32391999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
